Deregulation of the Histone Lysine-Specific Demethylase 1 Is Involved in Human Hepatocellular Carcinoma.
LSD1
hepatocellular carcinoma
histone demethylase
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
31
10
2019
revised:
23
11
2019
accepted:
26
11
2019
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
12
9
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. Given that the standard-of-care for advanced liver cancer is limited, there is an urgent need to develop a novel molecular targeted therapy to improve therapeutic outcomes for HCC. In order to tackle this issue, we conducted functional analysis of the histone lysine-specific demethylase (LSD1) to explore the possibility that this enzyme acts as a therapeutic target in HCC. According to immunohistochemical analysis, 232 of 303 (77%) HCC cases showed positive staining of LSD1 protein, and its expression was correlated with several clinicopathological characteristics, such as female gender, AFP (alpha-fetoprotein) levels, and HCV (hepatitis C virus) infectious. The survival curves for HCC using the Kaplan-Meier method and the log-rank test indicate that positive LSD1 protein expression was significantly associated with decreased rates of overall survival (OS) and disease-free survival (DFS); the multivariate analysis indicates that LSD1 expression was an independent prognostic factor for both OS and DFS in patients with HCC. In addition, knockout of LSD1 using the CRISPR/Cas9 system showed a significantly lower number of colony formation units (CFUs) and growth rate in both SNU-423 and SNU-475 HCC cell lines compared to the corresponding control cells. Moreover, LSD1 knockout decreased cells in S phase of SNU-423 and SNU-475 cells with increased levels of H3K4me1/2 and H3K9me1/2. Finally, we identified the signaling pathways regulated by LSD1 in HCC, including the retinoic acid (RA) pathway. Our findings imply that deregulation of LSD1 can be involved in HCC; further studies may explore the usefulness of LSD1 as a therapeutic target of HCC.
Identifiants
pubmed: 31805626
pii: biom9120810
doi: 10.3390/biom9120810
pmc: PMC6995592
pii:
doi:
Substances chimiques
Histone Demethylases
EC 1.14.11.-
KDM1A protein, human
EC 1.5.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Neoplasia. 2011 Aug;13(8):676-84
pubmed: 21847359
Oncotarget. 2018 Sep 28;9(76):34320-34335
pubmed: 30344945
Cell. 2004 Dec 29;119(7):941-53
pubmed: 15620353
BMC Cancer. 2018 Mar 22;18(1):317
pubmed: 29566670
Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188
pubmed: 29581250
Mol Cancer. 2011 May 28;10:65
pubmed: 21619671
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Haematologica. 2019 Jun;104(6):1156-1167
pubmed: 30514804
Nat Rev Cancer. 2015 Feb;15(2):110-24
pubmed: 25614009
Cancer Sci. 2016 Apr;107(4):377-84
pubmed: 26751963
Genes Dev. 2008 May 1;22(9):1115-40
pubmed: 18451103
Neoplasia. 2012 Jun;14(6):476-86
pubmed: 22787429
Carcinogenesis. 2008 Oct;29(10):1901-10
pubmed: 18632756
Int Urol Nephrol. 2015 Mar;47(3):485-90
pubmed: 25627913
Liver Int. 2019 Sep;39(9):1682-1691
pubmed: 30698907
Mol Cancer Res. 2015 Feb;13(2):293-304
pubmed: 25280969
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Nat Med. 2011 Mar;17(3):288-9
pubmed: 21383739
Curr Genomics. 2011 Apr;12(2):130-7
pubmed: 21966251
J Exp Clin Cancer Res. 2019 Jan 15;38(1):18
pubmed: 30646949
Cancer Res. 2006 Dec 1;66(23):11341-7
pubmed: 17145880
Cancer Res. 2009 Mar 1;69(5):2065-71
pubmed: 19223552
Cancer Lett. 2013 Aug 9;336(1):76-84
pubmed: 23603248
Neoplasia. 2011 Oct;13(10):887-98
pubmed: 22028615
Oncol Rep. 2011 Dec;26(6):1581-6
pubmed: 21874262
J Med Chem. 2019 Mar 28;62(6):2905-2915
pubmed: 30403487
Nature. 2005 Sep 15;437(7057):436-9
pubmed: 16079795
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):15-21
pubmed: 16706806
Nat Cell Biol. 2004 Aug;6(8):731-40
pubmed: 15235609
World J Gastroenterol. 2012 Dec 7;18(45):6651-6
pubmed: 23236241
Mol Cell Biol. 2010 Apr;30(8):1997-2005
pubmed: 20123967
Neoplasia. 2013 Nov;15(11):1251-61
pubmed: 24339737
Pediatr Blood Cancer. 2019 Sep;66(9):e27888
pubmed: 31207107
Cancer Prev Res (Phila). 2011 Dec;4(12):2051-61
pubmed: 21930796
World J Gastroenterol. 2019 Jun 21;25(23):2863-2877
pubmed: 31249445
Curr Cancer Drug Targets. 2012 Nov 1;12(9):1119-28
pubmed: 22873214
BMC Bioinformatics. 2017 Mar 2;18(1):142
pubmed: 28249561
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:33-7
pubmed: 23855293
PLoS One. 2012;7(4):e35065
pubmed: 22493729
Cells. 2019 Jun 18;8(6):
pubmed: 31216761
Nat Commun. 2019 Sep 19;10(1):4278
pubmed: 31537801
Chem Biol Drug Des. 2011 Aug;78(2):199-210
pubmed: 21564555
Nat Cell Biol. 2007 Mar;9(3):347-53
pubmed: 17277772
Elife. 2016 Feb 02;5:
pubmed: 26836306
Oncotarget. 2015 Jul 10;6(19):16939-50
pubmed: 26183527
Cell Physiol Biochem. 2013;31(6):854-62
pubmed: 23816987
Oncogene. 2018 Jan 25;37(4):534-543
pubmed: 28991226
Cancer Res. 2011 Feb 1;71(3):655-60
pubmed: 21115810
Curr Top Med Chem. 2013;13(21):2745-66
pubmed: 24083789
Diseases. 2015 Oct 28;3(4):294-305
pubmed: 28943626
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Mol Cancer. 2010 Mar 13;9:59
pubmed: 20226085
Cancer Sci. 2011 Jul;102(7):1298-305
pubmed: 21539681
Cancer Res. 2012 Jul 1;72(13):3217-27
pubmed: 22556262
Int J Cancer. 2011 Feb 1;128(3):574-86
pubmed: 20333681
Hepatology. 2019 Feb;69(2):785-802
pubmed: 30055117
Int J Cancer. 2013 Sep 1;133(5):1064-73
pubmed: 23400681
Genes Chromosomes Cancer. 2013 Feb;52(2):126-39
pubmed: 23011637
Int J Cancer. 2012 Aug 1;131(3):E179-89
pubmed: 22020899
Int J Cancer. 2011 Feb 1;128(3):562-73
pubmed: 20473859